Ueda Masami, Ikenaga Masakazu, Tanida Tsukasa, Taguchi Daisuke, Ikegami Mariko, Fukushima Shoko, Yoshida Shoma, Sekiguchi Naoko, Koh Masahiro, Iede Kiyotsugu, Tsuda Yujiro, Nakashima Shinsuke, Matsuyama Jin, Yasui Masayoshi, Yamada Terumasa
Dept. of Gastroenterological Surgery, Higashiosaka City Medical Center.
Gan To Kagaku Ryoho. 2020 Dec;47(13):1762-1764.
We report a case of a male in his sixties with appendiceal cancer who underwent radical resection following CAPOX plus bevacizumab neoadjuvant chemotherapy. The patient presented to our hospital with a chief complaint of chronic low abdominal pain. Contrast-enhanced CT before neoadjuvant chemotherapy revealed an inhomogeneous tumor in the ileocecal region. Invasion to the bladder and the sigmoid colon was also observed. A colonoscopy showed an elevated lesion, which was caused by extramural invasion to the sigmoid colon. Pathological examination of the sigmoid colon tumor revealed well differentiated tubular adenocarcinoma and KRAS codon13 G13D. Hence, we diagnosed the patient with locally advanced appendiceal cancer with invasion to the bladder and sigmoid colon. We administered CAPOX plus bevacizumab as neoadjuvant chemotherapy. Contrast-enhanced abdominal CT after neoadjuvant chemotherapy revealed shrinkage of the primary tumor and reduction in the invasion to the bladder and sigmoid colon. We performed ileocecal resection(+D3), a partial sigmoidectomy, and partial bladder resection on the 135th day from the diagnosis. The resected specimen showed an appendiceal tumor with invasion to the bladder and sigmoid colon. The pathological diagnosis was Ⅴ, yType 5, tub2>tub1, ypT4b, ypN0, ycH0, ycM0, ycPUL0, Ly1b, V1b(VB), Pn01b, pStage Ⅱa, and the histological treatment effect of preoperative therapy was Grade 1b. Our experience indicates that in patients with locally advanced appendiceal cancer, multimodal treatment with neoadjuvant chemotherapy is an effective option.
我们报告一例60多岁的男性阑尾癌患者,其在接受CAPOX联合贝伐单抗新辅助化疗后进行了根治性切除。该患者因慢性下腹部疼痛为主诉前来我院就诊。新辅助化疗前的增强CT显示回盲部区域有一个不均匀的肿瘤。还观察到肿瘤侵犯膀胱和乙状结肠。结肠镜检查显示有一个隆起病变,是由乙状结肠壁外侵犯引起的。乙状结肠肿瘤的病理检查显示为高分化管状腺癌和KRAS密码子13 G13D。因此,我们诊断该患者为局部晚期阑尾癌,侵犯膀胱和乙状结肠。我们给予CAPOX联合贝伐单抗作为新辅助化疗。新辅助化疗后的腹部增强CT显示原发肿瘤缩小,对膀胱和乙状结肠的侵犯减轻。在诊断后的第135天,我们进行了回盲部切除(+D3)、部分乙状结肠切除术和部分膀胱切除术。切除标本显示阑尾肿瘤侵犯膀胱和乙状结肠。病理诊断为Ⅴ,y型5,tub2>tub1,ypT4b,ypN0,ycH0,ycM0,ycPUL0,Ly1b,V1b(VB),Pn01b,pⅡa期,术前治疗的组织学治疗效果为1b级。我们的经验表明,对于局部晚期阑尾癌患者,新辅助化疗的多模式治疗是一种有效的选择。